Jesús Prìeto

31.2k total citations · 3 hit papers
606 papers, 24.6k citations indexed

About

Jesús Prìeto is a scholar working on Molecular Biology, Hepatology and Epidemiology. According to data from OpenAlex, Jesús Prìeto has authored 606 papers receiving a total of 24.6k indexed citations (citations by other indexed papers that have themselves been cited), including 219 papers in Molecular Biology, 193 papers in Hepatology and 168 papers in Epidemiology. Recurrent topics in Jesús Prìeto's work include Liver Disease Diagnosis and Treatment (102 papers), Virus-based gene therapy research (102 papers) and Hepatitis C virus research (81 papers). Jesús Prìeto is often cited by papers focused on Liver Disease Diagnosis and Treatment (102 papers), Virus-based gene therapy research (102 papers) and Hepatitis C virus research (81 papers). Jesús Prìeto collaborates with scholars based in Spain, United States and Germany. Jesús Prìeto's co-authors include Bruno Sangro, Cheng Qian, Ignacio Melero, Jorge Quiroga, Matías A. Ávila, Carmen Berasain, Juan José Lasarte, Pablo Sarobe, Francisco Borrás‐Cuesta and Alberto Castilla and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Jesús Prìeto

593 papers receiving 24.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C

2013 764 citations Bruno Sangro, José Ignacio Riezu‐Boj et al. profile →
Transforming Growth Factors β1 and α in Chronic Liver Disease

1991 563 citations Jesús Prìeto et al. profile →
Immunological landscape and immunotherapy of hepatocellular carcinoma

2015 470 citations Jesús Prìeto, Ignacio Melero et al. profile →

Peers

Countries citing papers authored by Jesús Prìeto

Since Specialization

Citations

This map shows the geographic impact of Jesús Prìeto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jesús Prìeto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jesús Prìeto more than expected).

Fields of papers citing papers by Jesús Prìeto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jesús Prìeto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jesús Prìeto. The network helps show where Jesús Prìeto may publish in the future.

Co-authorship network of co-authors of Jesús Prìeto

This figure shows the co-authorship network connecting the top 25 collaborators of Jesús Prìeto. A scholar is included among the top collaborators of Jesús Prìeto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jesús Prìeto. Jesús Prìeto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Recombinant porphobilinogen deaminase targeted to the liver corrects enzymopenia in a mouse model of acute intermittent porphyria 2022 ·Science Translational Medicine ·(unknown), (unknown), (unknown), María Merino, Lei Jiang, Ana Sampedro, Manuel Alegre, Fernando J. Corrales, Marı́a J. Garrido, Paolo G.V. Martini, José L. Lanciego, Jesús Prìeto, Pedro Berraondo, Antonio Fontanellas	12
2	Improvement of Adeno-Associated Virus-Mediated Liver Transduction Efficacy by Regional Administration in Macaca fascicularis 2017 ·Nerea Zabaleta, (unknown), (unknown), Mirja Hommel, (unknown), Rubén Hernández-Alcoceba, Jesús Prìeto, José Ignacio Bilbao, Gloria González‐Aseguinolaza	8
3	Assessment of Biliary Bicarbonate Secretion in Humans by Positron Emission Tomography 2017 ·Revista de medicina de la Universidad de Navarra ·Jesús Prìeto, Nicolás Garcı́a, Josep M. Martí‐Climent, (unknown), J Richter, Juan Francisco Medina Gallardo	24
4	MEF2D Transduces Microenvironment Stimuli to ZEB1 to Promote Epithelial–Mesenchymal Transition and Metastasis in Colorectal Cancer 2016 ·Cancer Research ·Li Su, Yongli Luo, Zhi Yang, H. J. Yang, Chao Yao, Feifei Cheng, Juanjuan Shan, Jun Chen, Fangfang Li, Limei Liu, Chungang Liu, Yanmin Xu, Lupin Jiang, Deyu Guo, Jesús Prìeto, Matías A. Ávila, Junjie Shen, Cheng Qian	57
5	Transient Expression of Transgenic IL-12 in Mouse Liver Triggers Unremitting Inflammation Mimicking Human Autoimmune Hepatitis 2016 ·The Journal of Immunology ·(unknown), Marianna Di Scala, Eduardo Salido, Esperanza López‐Franco, (unknown), (unknown), Juana Merino, Rafael Aldabe, Jesús Prìeto, Gloria González‐Aseguinolaza	24
6	Overexpression of the Transcription Factor MEF2D in Hepatocellular Carcinoma Sustains Malignant Character by Suppressing G2–M Transition Genes 2014 ·Cancer Research ·Leina Ma, Jia Liu, Limei Liu, Guangjie Duan, Qingliang Wang, Yanmin Xu, X Y Feng, Juanjuan Shan, Junjie Shen, Zhi Yang, Ping Bie, You‐Hong Cui, Xiu‐Wu Bian, Jesús Prìeto, Matías A. Ávila, Cheng Qian	74
7	Antitumor Immunotherapeutic and Toxic Properties of an HDL-Conjugated Chimeric IL-15 Fusion Protein 2012 ·Cancer Research ·María C. Ochoa, Jessica Fioravanti, Inmaculada Rodríguez, Sandra Hervás‐Stubbs, Arantza Azpilikueta, Guillermo Mazzolini, Alfonso Gúrpide, Jesús Prìeto, Julián Pardo, Pedro Berraondo, Ignacio Melero	39
8	Adjuvant Combination and Antigen Targeting as a Strategy to Induce Polyfunctional and High-Avidity T-Cell Responses against Poorly Immunogenic Tumors 2011 ·Cancer Research ·Fernando Aranda, Diana Llópiz, Nancy Díaz‐Valdés, José Ignacio Riezu‐Boj, Jaione Bezunartea, Marta Ruiz, Marta Martínez, (unknown), Cristina Mansilla, Jesús Prìeto, Juan José Lasarte, Francisco Borrás‐Cuesta, Pablo Sarobe	63
9	Biliary secretion of S‐nitrosoglutathione is involved in the hypercholeresis induced by ursodeoxycholic acid in the normal rat† 2010 ·Hepatology ·Carlos M. Rodríguez‐Ortigosa, Jesús M. Bañales, (unknown), Iker Uriarte, José J.G. Marı́n, Fernando J. Corrales, Juan Francisco Medina Gallardo, Jesús Prìeto	17
10	Wilms' Tumor 1 Gene Expression in Hepatocellular Carcinoma Promotes Cell Dedifferentiation and Resistance to Chemotherapy 2009 ·Cancer Research ·María J. Perugorria, Josefa Castillo, María U. Latasa, Saioa Goñi, Víctor Segura, Bruno Sangro, Jesús Prìeto, Matías A. Ávila, Carmen Berasain	46
11	Blockade of Wnt Signaling Inhibits Angiogenesis and Tumor Growth in Hepatocellular Carcinoma 2009 ·Cancer Research ·Jie Hu, Aiwen Dong, (unknown), Juanjuan Shan, Miłosz Kawa, Eduardo Martínez‐Ansó, Jesús Prìeto, Cheng Qian	105
12	Mitochondrial Cholesterol Contributes to Chemotherapy Resistance in Hepatocellular Carcinoma 2008 ·Cancer Research ·Joan Montero, Albert Morales, Laura Llacuna, Josep M. Lluis, Oihana Terrones, Gorka Basáñez, Bruno Antonsson, Jesús Prìeto, Carmen García‐Ruiz, Anna Colell, José C. Fernández‐Checa	232
13	Low Surface Expression of B7-1 (CD80) Is an Immunoescape Mechanism of Colon Carcinoma 2006 ·Cancer Research ·Iñigo Tirapu, Eduardo Huarte, Cristiana Guiducci, Ainhoa Arina, Mikel Zaratiegui, Oihana Murillo, Álvaro González, Carmen Berasain, Pedro Berraondo, Puri Fortes, Jesús Prìeto, Mario P. Colombo, Lieping Chen, Ignacio Melero	116
14	Increased Efficacy and Safety in the Treatment of Experimental Liver Cancer with a Novel Adenovirus-Alphavirus Hybrid Vector 2006 ·Cancer Research ·(unknown), Juan R. Rodríguez-Madoz, Pilar Alzuguren, (unknown), M. Gabriela Kramer, Stefan Kochanek, Jesús Prìeto, Cristian Smerdou, Cheng Qian	28
15	Inhibiting expression of specific genes in mammalian cells with 5′ end-mutated U1 small nuclear RNAs targeted to terminal exons of pre-mRNA 2003 ·Proceedings of the National Academy of Sciences ·Puri Fortes, Yolanda Cuevas, Fei Guan, Peng Liu, (unknown), (unknown), Maria Luz Martínez‐Chantar, Jesús Prìeto, David W. Rowe, Samuel Gunderson	69
16	Anti-ICAM-2 monoclonal antibody synergizes with intratumor gene transfer of interleukin-12 inhibiting activation-induced T-cell death. 2003 ·PubMed ·Ignacio Melero, (unknown), Iñigo Tirapu, Ainhoa Arina, Guillermo Mazzolini, Elena Baixerás, Esperanza Feijoó, Carlos Alfaro, Cheng Qian, Jesús Prìeto	7
17	An anti-ICAM-2 (CD102) monoclonal antibody induces immune-mediated regressions of transplanted ICAM-2-negative colon carcinomas. 2002 ·PubMed ·Ignacio Melero, (unknown), Ángel L. Corbí, Miguel Relloso, Guillermo Mazzolini, Volker Schmitz, Mercedes Rodrı́guez-Calvillo, Iñigo Tirapu, Emilio Camafeita, Juan Pablo Albar, Jesús Prìeto	17
18	Decreased Anion Exchanger 2 Immunoreactivity in the Liver of Patients With Primary Biliary Cirrhosis 1997 ·Hepatology ·Juan F. Medina, Eduardo Martínez‐Ansó, J. J. Vázquez, Jesús Prìeto	148
19	Cloning and expression of theMycobacterium fortuitumSuperoxide dismutase gene 1995 ·FEMS Microbiology Letters ·(unknown), Pilar Domenech, Jesús Prìeto, (unknown)	11
20	N -Acetyl Cysteine Enhances the Response to Interferon-α in Chronic Hepatitis C: A Pilot Study 1993 ·Journal of Interferon Research ·Óscar Beloqui, Jesús Prìeto, José Antonio Suárez, Beatriz Gil, (unknown), Nicolás Garcı́a, M.P. Civeira	76

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact